Hot Life Science Investor Mandate 1: Corporate Venture Capital Arm Leverages Preclinical Services in Exchange for Equity

5 Dec

The corporate venture capital arm of a larger firm based in the Eastern US makes equity investments in early stage life science companies through its network of high net worth individuals, and typically invests between $500,000 to $1 million. The firm also looks to leverage its affiliate company’s array of preclinical services to its portfolio companies in exchange for equity. The firm looks to invest in companies located throughout the U.S., and plans to make 2-3 allocations over the next 6-9 months.

The corporate venture capital is currently looking for companies developing therapeutics, and considers both small molecules and biologics. The firm is open to most indications, but is generally not interested in companies in the cardiovascular, CNS, glioblastoma and pancreatic cancer spaces. The firm is very interested in other areas of oncology as well as ocular and dermal indications, areas in which the firm’s affiliated labs have highly specialized technology that can add value. The firm is looking for companies that are 3-6 months pre-IND enabling phase. The firm is not interested in allocating to companies that are in the lead optimization phase, as they cannot leverage preclinical services to benefit the company.

The CVC generally does not lead investment rounds and acts as a co-investor, but will look to take either a board or board observer seat into companies.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s

%d bloggers like this: